Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Drug Insights
4 min read
Pharmaceutical Insights: Granisetron's R&D Progress and its Mechanism of Action on Drug Target
8 October 2023
This article summarized the latest R&D progress of Granisetron, the Mechanism of Action for Granisetron, and the drug target R&D trends for Granisetron.
Latest Hotspot
3 min read
Initial Recipient of Omisirge™ (omidubicel-onlv) by Gamida Cell Administered to First Patient
8 October 2023
Gamida Cell Ltd. has declared that the initial patient has been subjected to a stem cell transplantation procedure using Omisirge (omidubicel-onlv).
Drug Insights
4 min read
Exploring Gliclazide's Revolutionary R&D Successes and its Mechanism of Action on Drug Target
8 October 2023
This article summarized the latest R&D progress of Gliclazide, the Mechanism of Action for Gliclazide, and the drug target R&D trends for Gliclazide.
Latest Hotspot
4 min read
Abeona Therapeutics has requested a U.S. FDA Biologics License for expedited review of EB-101, a treatment for Recessive Dystrophic Epidermolysis Bullosa patients
8 October 2023
Abeona Therapeutics Inc. has reported that they've lodged a BLA with U.S. FDA with a request to endorse EB-101.
Drug Insights
4 min read
Decoding Fosfomycin tromethamine: A Comprehensive Study of its R&D Trends and Mechanism on Drug Target
8 October 2023
This article summarized the latest R&D progress of Fosfomycin tromethamine, the Mechanism of Action for Fosfomycin tromethamine, and the drug target R&D trends for Fosfomycin tromethamine.
Latest Hotspot
3 min read
AltruBio declares FDA approval on IND submission for ALTB-268, an Immune Checkpoint Booster, triggering a Phase 2 Clinical Study for dealing with Ulcerative Colitis
8 October 2023
The US FDA approved AltruBio Inc.'s IND request, allowing Phase 2 clinical trials to start for its immune checkpoint booster, ALTB-268, for ulcerative colitis.
Drug Insights
4 min read
Deep Scientific Insights on Lanthanum carbonate's R&D Progress, Mechanism of Action, and Drug Target
8 October 2023
This article summarized the latest R&D progress of Lanthanum carbonate, the Mechanism of Action for Lanthanum carbonate, and the drug target R&D trends for Lanthanum carbonate.
Latest Hotspot
3 min read
Alfasigma set to purchase Intercept Pharmaceuticals at $19.00 each stock in cash, broadening international reach in unusual and critical liver ailments
8 October 2023
Intercept's principal drug is Ocaliva® (obeticholic acid), an FDA-approved farnesoid X receptor agonist in the United States and numerous other regions.
Drug Insights
4 min read
An In-depth Analysis of Flutamide's R&D Progress and Mechanism of Action on Drug Target
8 October 2023
This article summarized the latest R&D progress of Flutamide, the Mechanism of Action for Flutamide, and the drug target R&D trends for Flutamide.
Latest Hotspot
3 min read
Gracell Biotechnologies starts dosing in US Phase 1b/2 trial assessing GC012F's efficacy for treating recurrent or resistant multiple myeloma
8 October 2023
Gracell Biotechnologies Inc. has announced that the initial patient in the US has begun treatment in a Phase 1b/2 clinical trial for it's foremost candidate, GC012F, targeting patients with recurrent or resistant multiple myeloma.
Drug Insights
4 min read
Flunisolide: Detailed Review of its Transformative R&D Success, Mechanism of Action, and Drug Target
7 October 2023
This article summarized the latest R&D progress of Flunisolide, the Mechanism of Action for Flunisolide, and the drug target R&D trends for Flunisolide.
Latest Hotspot
3 min read
Adverum Biotechnologies reported encouraging Aflibercept Protein level results from their LUNA Phase 2 study
7 October 2023
Adverum Biotechnologies has released early findings on aflibercept protein activity from its ongoing Phase 2 LUNA study.